What Ind-Swift Laboratories does

Ind-Swift Laboratories Limited is an Indian pharmaceutical manufacturer founded in 1995 and headquartered in Chandigarh, India, listed on the Bombay Stock Exchange (bom:INDSWFTLAB). Historically, the company operated as an integrated pharmaceutical organization manufacturing active pharmaceutical ingredients (APIs), intermediates, and formulations, serving the pharmaceutical industry across both generic API supply and Contract Research and Manufacturing Services (CRAMS).

In March 2024, Ind-Swift Laboratories executed a transformational divestiture, carving out its generic API and CRAMS business into a special purpose vehicle, Synthimed Labs, which was acquired by India Resurgence Fund — a joint venture between Piramal Group and Bain Capital — for ₹1,650 crore. The carved-out entity subsequently reported ₹1,452 crore in revenue and ₹469 crore in EBITDA for FY25, with IndiaRF later engaging Rothschild & Co to seek a minority stake sale at an implied ~$1 billion valuation. Post-divestiture, Ind-Swift Laboratories continues as an independently listed entity with its residual formulations and specialty operations, though its standalone post-carve-out product portfolio and financials are not detailed in available source data.

Leadership is anchored by NR Munjal as Chairman & Managing Director. The company's equity has experienced significant price appreciation between April 2025 and mid-2026, with total returns of 59-70% reported by various sources, alongside notable shareholder activity including HCP Investments' sale of a 6.65% stake absorbed by institutional buyers. No AI/ML capabilities, named product brands, customer logos, or pricing model details are disclosed in the source material.

Name

Ind-Swift Laboratories

Legal name

Ind-Swift Laboratories Limited

Website

https://indswiftlabs.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ind-Swift Laboratories is an Indian pharmaceutical manufacturer (founded 1995, BSE-listed) that produced APIs, intermediates, and formulations; it divested its generic API and CRAMS business to IndiaRF in March 2024 and continues as a listed residual entity.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (APIs and Formulations)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Active pharmaceutical ingredients
• API intermediates
• Pharmaceutical formulations
• Contract manufacturing
• Generic drug manufacturing

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Core offering

Ind-Swift Laboratories is an integrated Indian pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), intermediates, and formulations for the healthcare industry. Historically, the company also provided contract research and manufacturing services (CRAMS); however, in March 2024 the generic API and CRAMS business was carved out into Synthimed Labs and sold to India Resurgence Fund (IndiaRF) for ₹1,650 crore.

Product overview

Ind-Swift Laboratories is an Indian pharmaceutical manufacturer. Based on available source data, no specific named products, brand offerings, or product portfolio details are identified. A divestment transaction reference mentions Synthimed Labs was carved out from Ind-Swift Laboratories' generic API and CRAMS business in March 2024, but no individual product names are provided in the source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Manufacture of active pharmaceutical ingredients supplied to pharmaceutical formulators and drug makers; generic API business was carved out into Synthimed Labs in March 2024.
• Pharmaceutical Intermediates Production of chemical intermediates used in the synthesis of APIs, supplied to other pharmaceutical manufacturers.
• Pharmaceutical Formulations Finished dosage formulations for the healthcare market, leveraging the company's integrated API and intermediates capabilities.
• Contract Research and Manufacturing Services (CRAMS) Contract research and contract manufacturing services provided to pharmaceutical clients; this business unit was carved out into Synthimed Labs and sold to IndiaRF in March 2024 for ₹1,650 crore.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Synthimed LabsmajorOthersSynthimed Labs was established in March 2024 as a special purpose vehicle to house the carved-out generic API and CRAMS business acquired from Ind-Swift Laboratories. The business reported revenues of ₹1,452 crore with EBITDA of ₹469 crore in FY25.

Scale indicators7 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Suven Pharmaceuticals: Indian CRAMS-focused pharma company with NCE development and API manufacturing; comparable CRAMS-led business model to Ind-Swift's divested business.
• Neuland Laboratories: Indian API manufacturer with custom synthesis and CRAMS services; serves similar B2B pharma customer base with comparable product technology.
• Laurus Labs: Indian API, intermediates, and CDMO manufacturer with comparable CRAMS unit; closest like-for-like peer to Ind-Swift on business model and customer mix.
• Granules India: Indian API and finished dosage manufacturer with focus on regulated markets; comparable on API-intermediates-formulations integration similar to Ind-Swift's model.
• Divis Laboratories: Indian API and intermediates manufacturer with strong CRAMS exposure; directly comparable to Ind-Swift's pre-divestiture platform and serves the same regulated markets.
• Aurobindo Pharma: Large Indian vertically-integrated API and formulations manufacturer; directly comparable end-to-end pharma business including active pharmaceutical ingredient manufacturing.

Broad incumbents

• Cipla: Major Indian pharma manufacturer with API manufacturing and a global formulations franchise; comparable on finished dosage manufacturing capability even if much larger and broader.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with API and formulations businesses across global regulated and emerging markets; broader portfolio but overlaps with Ind-Swift on API exposure.
• Piramal Pharma: Indian pharma and CDMO major that, via IndiaRF (Piramal-Bain Capital JV), acquired Ind-Swift's API/CRAMS business; a relevant counterparty and broad incumbent in adjacent pharma/CDMO services.

Emerging players

• Sequent Scientific: Indian API manufacturer focused on animal and human health APIs; smaller-scale emerging player with comparable manufacturing platform and customer base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ind-Swift Laboratories